HONOR and Gameloft’s Gaming Revolutionby Lilu Anderson 13.02.2024HONOR has partnered with Gameloft to revolutionize gaming on foldable smartphones, aiming to run Asphalt 9: Legends at 120 FPS ...
Coca-Cola HBC AG: 2023 Earnings Outlookby Mark Eisenberg 13.02.2024Coca-Cola HBC AG is set to report strong financial results for 2023, with significant growth in key areas. Challenges exist, ...
Thyssenkrupp Earnings Dip: Investor Concerns Riseby Mark Eisenberg 13.02.2024Thyssenkrupp is set to report Q1 results with a projected drop in revenue and profit. Investors are eagerly awaiting updates ...
Ethereum & Galaxy Fox: Explosive Growth Aheadby John Darbie 13.02.2024Reputable analyst predicts Ethereum could reach $27,000 as Galaxy Fox gains momentum. Ethereum's growth driven by PoS transition, DeFi/NFT popularity, ...
Sony Revamps PS4, PS5 Sales Data: VR’s Riseby Lilu Anderson 13.02.2024Sony has revised its software sales figures for PlayStation to include download-only titles and VR games, reflecting the growing popularity ...
Citi Raises Target for Arista Networks to $300by Mark Eisenberg 13.02.2024Citi maintains a positive outlook on Arista Networks despite recent stock declines, with a target price of $300. The company's ...
ZoomInfo’s Stock Soars: Jefferies Ups Target to $24by Mark Eisenberg 13.02.2024ZoomInfo Technologies receives positive outlook adjustment from Jefferies, with raised price target and Buy rating. Strong financial position, impressive profit ...
Amazon Faces Lawsuit Over ‘Buy Box’ Manipulation: Implications Substantialby Mark Eisenberg 13.02.2024Amazon is facing a class-action lawsuit over the manipulation of its "Buy Box" feature, which allegedly drives customers to overpay ...
TUI Surprises with €6 Million Quarterly Profitby Mark Eisenberg 13.02.2024TUI, the travel giant, has surprised investors by posting a quarterly profit of €6 million, surpassing expectations. The company's strong ...
Eli Lilly’s Orfoscerinib: Jefferies Raises Price Targetby Mark Eisenberg 13.02.2024Investment banking firm Jefferies raises Eli Lilly's price target based on optimism over orfoscerinib, indicating strong confidence in its potential. ...